Beta Bionics (NASDAQ:BBNX) Upgraded by Leerink Partnrs to Strong-Buy Rating

Leerink Partnrs upgraded shares of Beta Bionics (NASDAQ:BBNX) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

A number of other analysts have also weighed in on BBNX. Piper Sandler started coverage on Beta Bionics in a research note on Monday. They issued an “overweight” rating and a $26.00 target price for the company. LADENBURG THALM/SH SH assumed coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of Beta Bionics in a research note on Monday. They issued a “buy” rating and a $25.00 target price for the company. Robert W. Baird initiated coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Bank of America began coverage on shares of Beta Bionics in a report on Monday. They issued a “buy” rating for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Up 0.1 %

NASDAQ BBNX opened at $20.60 on Monday. Beta Bionics has a one year low of $20.00 and a one year high of $24.50.

Insider Transactions at Beta Bionics

In related news, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.